This week, the ratings of 4 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Flamel Technologies SA Sponsored ADR’s (FLML) rating worsens to a F from the company’s D rating a week ago. Flamel Technologies SA Sponsored ADR develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. The company also gets F’s in earnings growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of FLML stock.

This is a rough week for Marinus Pharmaceuticals Inc (MRNS). The company’s rating falls to F from the previous week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRNS stock.

CymaBay Therapeutics, Inc. (CBAY) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CBAY stock.

Ritter Pharmaceuticals, Inc.’s (RTTR) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of RTTR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.